BEIJING, April 14 – RIA Novosti. The Chinese authorities have approved the clinical trials have three was developed in the country vaccines against a new type of coronavirus, said at a press conference on Tuesday, the head of the Department for scientific and technological development of the Ministry of science and technology of China Have Wangbing.
“currently, three vaccines have received approval for clinical trials, among them the first approved the vaccine based on adenoviral vectors developed by a team of academician Chen Wei,” – said At Wangbing.
According to him, the first phase of clinical trials indicated the vaccine already completed, April 9 a team of academician Chen Wei has already started to recruit volunteers for the second phase, “the world’s first vaccine against COVID-19, which has already reached the second phase of clinical trials.”
“the Twelfth of April the State administration for supervision of food and drugs approved the initiation of clinical trials of inactivated vaccine, developed jointly by Wuhan Institute of Virology under the Chinese Academy of Sciences and Wuhan Institute of biological products (part of the Sinopharm Group – ed.)”, he said.
According to officials, on Monday a permit for the conduct of clinical trials of inactivated vaccine from COVID-19 also received a Beijing company Sinovac Research & Development Co.
Clinical trials of the first developed in China of a vaccine against a new type of coronavirus began in mid-March, which was attended by 108 volunteers, which were divided into 3 groups of 36 people. The first group of volunteers were injected with low dose of vaccine, the second is average, third is high. The results of the first phase of testing is still unknown. Clinical trials of the vaccine will take place in the period from 16 March to 31 December 2020.
once in China, an outbreak of coronavirus, was necessary as soon as possible to begin the development of the vaccine, local scientists and the profile of the company did not concentrate on only one type of vaccine and began to explore five: recombinant subunit vaccine, inactivated vaccine, vaccine based on adenovirus vector vaccine based on nucleic acids and live-attenuated influenza vaccine.
According to the chief epidemiologist Zhong Nanshan, the country’s fastest going development of the vaccine based on adenovirus vector and inactivated vaccines. He also noted that usually after clinical trials some time need to monitor the volunteers who participated in the research, it usually takes from one to two years, but given the speed and magnitude of COVID-19, if effective, to produce a vaccine to market can be quicker than usual.
the Latest data on the situation of COVID-19 in Russia and the world presented on the portal stopmanager.of the Russian Federation.
